--- title: "Morning Trend | SINO BIOPHARM rebounds from low points, will a rebound window open?" description: "SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall dow" type: "news" locale: "en" url: "https://longbridge.com/en/news/274497353.md" published_at: "2026-02-03T01:00:00.000Z" --- # Morning Trend | SINO BIOPHARM rebounds from low points, will a rebound window open? > SINO BIOPHARM (1177.HK) has recently experienced a prolonged period of low price fluctuations, with daily candlesticks showing slight alternation between bullish and bearish trends, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking and market participants showing strong wait-and-see sentiment. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, indicating a large divergence between bulls and bears in the short term. Fundamentally, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it is affected by industry medical insurance cost control, centralized procurement pressures, and a slowdown in sequential performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading enthusiasm. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic headwinds that have further suppressed risk appetite for capital. Technically, current support is located in the HKD 3.5-3.8 range, which has historically seen rebounds after multiple touches. However, the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. Conversely, if the price breaks support on low volume, there may be a risk of inertia downward movement. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes alongside unusual movements in incremental funds, light participation in short-term opportunities may be considered, with an overall focus on stability and risk control as a priority SINO BIOPHARM (1177.HK) has recently experienced a prolonged low-level fluctuation in its stock price, with daily candles showing slight alternation between bullish and bearish, and an overall downward shift in focus. In the past few trading days, the stock price has retraced to the vicinity of previous low ranges, with trading volume continuously shrinking, and there is a strong wait-and-see sentiment among incremental funds in the market. From a technical perspective, the MACD indicator remains in a death cross, with significant green bars, indicating a large divergence between bulls and bears in the short term. On the fundamental side, the company focuses on its pharmaceutical core business, possessing strong R&D capabilities and product resources. However, it has been affected by industry medical insurance cost control, centralized procurement pressure, and a slowdown in quarter-on-quarter performance growth, leading to weakened market confidence. The overall valuation of the Hong Kong stock pharmaceutical sector is under pressure, with limited inflow momentum from northbound and foreign capital, and a noticeable decline in trading enthusiasm. Meanwhile, the global interest rate hike cycle and the continued weakness of the Hong Kong dollar are also macroeconomic negatives that further suppress risk appetite for funds. From a technical standpoint, the current support level is in the range of HKD 3.5-3.8, which has historically seen rebounds after multiple touches in this area, but the sustainability of recent rebounds has been average. If there is a short-term increase in volume and the price stabilizes above HKD 4, it may open a window for a rebound and repair the weak pattern. If the price breaks the support level on reduced volume, there may be a risk of inertia downward. Investors are advised to closely monitor the distribution of main funds and the short-term sector atmosphere, and to avoid blindly entering large positions until technical signals are clear. If a rebound stabilizes along with unusual movements in incremental funds, it may be appropriate to participate in short-term opportunities with a light position, with an overall focus on stability and risk control as a priority ### Related Stocks - [01530.HK - 3SBIO](https://longbridge.com/en/quote/01530.HK.md) - [01177.HK - SINO BIOPHARM](https://longbridge.com/en/quote/01177.HK.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274491341.md) | | 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274496124.md) | | Madrigal 製藥｜8-K：2025 財年 Q4 營收 3.21 億美元超過預期 | | [Link](https://longbridge.com/en/news/276330350.md) | | 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274494597.md) | | 早盤趨勢｜中國生物製藥回踩低點，反彈窗口會否開啓？ | 中國生物製藥（1177.HK）近期股價持續低位震盪整理，日線呈現小幅陰陽交替，整體重心下移。近幾個交易日，股價回踩至前低區間附近，成交量持續萎縮，場內增量資金觀望情緒濃厚。從技術面看，MACD 指標依舊死叉，綠柱顯著，短線多空分歧較大。 基 | [Link](https://longbridge.com/en/news/274492204.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.